Abstract | BACKGROUND: METHODS: Randomized clinical trials comparing hyperoncotic albumin with a control regimen for volume expansion were sought by multiple methods, including computer searches of bibliographic databases, perusal of reference lists, and manual searching. Major findings were qualitatively summarized. In addition, a quantitative meta-analysis was performed on available survival data. RESULTS: CONCLUSION: In some clinical indications, randomized trial evidence has suggested certain benefits of hyperoncotic albumin such as reductions in morbidity, renal impairment and edema. However, further clinical trials are needed, particularly in surgery, trauma and sepsis.
|
Authors | Matthias Jacob, Daniel Chappell, Peter Conzen, Mahlon M Wilkes, Bernhard F Becker, Markus Rehm |
Journal | Critical care (London, England)
(Crit Care)
Vol. 12
Issue 2
Pg. R34
( 2008)
ISSN: 1466-609X [Electronic] England |
PMID | 18318896
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Chemical References |
- Albumins
- Plasma Substitutes
- Solutions
- hyperoncotic albumin
|
Topics |
- Albumins
(therapeutic use)
- Edema
(prevention & control)
- Humans
- Hypovolemia
(therapy)
- Plasma Substitutes
(therapeutic use)
- Randomized Controlled Trials as Topic
- Resuscitation
(methods)
- Solutions
|